Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A414476-5mg | 5mg | In stock | $53.90 | |
A414476-10mg | 10mg | In stock | $88.90 | |
A414476-25mg | 25mg | In stock | $187.90 | |
A414476-50mg | 50mg | In stock | $305.90 | |
A414476-100mg | 100mg | In stock | $494.90 |
Dehydrogenase Inhibitors
Synonyms | 2-[2,6-difluoro-4-(3-methoxyphenyl)anilino]pyridine-3-carboxylic acid | ASALN003 | UNII-I58WE41H6X | MFCD32215342 | GLXC-26306 | BDBM119812 | AI3-27396 | SY270741 | 1035688-66-4 | CAS-135-23-9 | CS-0104387 | MS-25575 | 2-[(3,5-difluoro-3'-methoxy-4-biphen |
---|---|
Specifications & Purity | Moligand™, ≥96% |
Biochemical and Physiological Mechanisms | ASLAN003 (LAS 186323) is a potent and orally active inhibitor of DHODH (Dihydroorotate dehydrogenase) with IC50 of 35 nM for human DHODH enzyme activity. ASLAN003 impairs protein synthesis and induces the differentiation and apoptosis transcriptional prog |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Dihydroorotate dehydrogenase inhibitor |
Product Description | Information ASLAN003 ASLAN003 (LAS 186323) is a potent and orally active inhibitor of DHODH (Dihydroorotate dehydrogenase) with IC50 of 35 nM for human DHODH enzyme activity. ASLAN003 impairs protein synthesis and induces the differentiation and apoptosis transcriptional program in acute myeloid leukemia (AML) cells via activation of AP-1 transcription factors. Targets AP-1 ; human DHODH (Cell-free assay) ; 35 nM In vitro ASLAN003 is a highly potent dihydroorotate dehydrogenase inhibitor that induces differentiation, as well as reducing cell proliferation and viability, of AML cell lines and primary AML blasts including chemoresistant cells. Apoptotic pathways are triggered by ASLAN003, and this drug also significantly inhibits protein synthesis and activates AP-1 transcription, contributing to its capacity to promote differentiation. In vivo ASLAN003 substantially reduces leukemic burden and prolongs survival in AML xenograft mice and AML patient-derived xenograft models. ASLAN003 has no evident effect on normal hematopoietic cells and exhibits excellent safety profiles in mice, even after a prolonged period of administration. Cell Research(from reference) Cell lines:MOLM-14 cells, KG-1 cells Concentrations:1 μM, 2 μM Incubation Time:1 h |
ALogP | 4.311 |
---|---|
HBD Count | 1 |
Rotatable Bond | 5 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | 2-[2,6-difluoro-4-(3-methoxyphenyl)anilino]pyridine-3-carboxylic acid |
---|---|
INCHI | InChI=1S/C19H14F2N2O3/c1-26-13-5-2-4-11(8-13)12-9-15(20)17(16(21)10-12)23-18-14(19(24)25)6-3-7-22-18/h2-10H,1H3,(H,22,23)(H,24,25) |
InChi Key | OMPATGZMNFWVOH-UHFFFAOYSA-N |
Canonical SMILES | COC1=CC=CC(=C1)C2=CC(=C(C(=C2)F)NC3=C(C=CC=N3)C(=O)O)F |
Isomeric SMILES | COC1=CC=CC(=C1)C2=CC(=C(C(=C2)F)NC3=C(C=CC=N3)C(=O)O)F |
PubChem CID | 24986824 |
Molecular Weight | 356.32 |
PubChem CID | 24986824 |
---|---|
CAS Registry No. | 1035688-66-4 |
ChEMBL Ligand | CHEMBL2263632 |
BindingDB Ligand | 119812 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
H2218359 | Certificate of Analysis | Jun 07, 2022 | A414476 |
H2218366 | Certificate of Analysis | Jun 07, 2022 | A414476 |
H2218368 | Certificate of Analysis | Jun 07, 2022 | A414476 |
H2218369 | Certificate of Analysis | Jun 07, 2022 | A414476 |
H2218387 | Certificate of Analysis | Jun 07, 2022 | A414476 |
Solubility | Solubility (25°C) In vitro DMSO: 71 mg/mL (199.25 mM); Water: Insoluble; Ethanol: Insoluble; |
---|---|
DMSO(mg / mL) Max Solubility | 71 |
DMSO(mM) Max Solubility | 199.259092950157 |
Water(mg / mL) Max Solubility | <1 |
Pictogram(s) | GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H315:Causes skin irritation H319:Causes serious eye irritation H335:May cause respiratory irritation H302:Harmful if swallowed |
Precautionary Statements | P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. P280:Wear protective gloves/protective clothing/eye protection/face protection. |
1. Zhou J, Yiying Quah J, Ng Y, Chooi JY, Hui-Min Toh S, Lin B, Zea Tan T, Hosoi H, Osato M, Seet Q et al.. (2020) ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia.. Haematologica, 105 (9): (2286-2297). [PMID:33054053] [10.1021/op500134e] |